Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.72
-$0.33(-5.45%)
At close: 4:00 PM EDT
$5.72
-$0.33(-5.45%)
Day’s Range― - ―
52-Week Range$3.10 - $8.68
Previous CloseN/A
Volume192.98K
Average Volume (3M)100.95K
Market Cap
$725.69M
Enterprise Value$380.21
Total Cash (Recent Filing)$107.67M
Total Debt (Recent Filing)$61.83M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside74.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$93.38M
Bulls Say, Bears Say
Bulls Say
Durable Revenue GrowthSustained growth in revenue, analysis volumes and U.S. activity indicates expanding platform adoption. The raised full-year outlook supports a durable demand trend rather than reliance solely on isolated contracts or temporary market conditions.
High Retention And Low ChurnHigh net retention and minimal churn suggest customers deepen usage over time and that the platform is embedded in diagnostic workflows. This supports recurring revenue quality, customer lifetime value and a stronger competitive position.
Strategic Precision-Oncology PartnershipsPartnerships with major oncology institutions and biopharma can expand access to clinical datasets, regulated diagnostics and evidence-generation programs. If executed, they could strengthen SOPHiA’s role as infrastructure for precision oncology.
Bears Say
Severe Ongoing UnprofitabilityThe company remains far from sustainable operating profitability despite revenue growth. Persistently large losses increase execution risk and could require additional financing before the platform generates sufficient operating leverage.
Persistent Cash BurnNegative operating and free cash flow means growth is not yet self-funded. Continued cash consumption can increase dependence on equity or other financing, potentially limiting strategic flexibility if the path to breakeven is delayed.
Margin Pressure And Conversion DelaysLower-margin biopharma and services work, higher infrastructure costs and onboarding bottlenecks may slow operating leverage. These factors could defer the benefits of new customer wins and make the guided breakeven timeline harder to achieve.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $3.10 and its highest was $8.68 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $725.69M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.09.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.2.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 83,895,260 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went up 20.211%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (74.83% Upside)
$10.00 (74.83% Upside)
Blogger Sentiment
Bearish
SOPH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.68%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS (SOPH) is a healthcare technology company that provides a cloud-based software and data analytics platform used by clinical laboratories and hospitals to analyze complex medical data—primarily genomic sequencing data—to support clinical decision-making in areas such as oncology and inherited/genetic diseases. The company’s core offering is its SOPHiA DDM platform, which standardizes and analyzes raw sequencing outputs and generates results that can be used by clinicians and lab professionals in routine diagnostics and research workflows.
SOPH Company Deck
SOPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial narrative: accelerating top-line growth (27% YoY), record analysis volumes (+22%), exceptional U.S. momentum (U.S. revenue +64%), materially improved adjusted EBITDA (27% improvement) and strategic, value-creating partnerships (AstraZeneca CDx wins and MSK JV MOU). These positives were balanced against margin pressure from growing pharma and services revenue, one-off legal and restructuring costs, an implementation backlog, and the fact the company remains adjusted EBITDA negative for 2026. On balance, the strategic wins, raised guidance, improved operating leverage, and a strengthened cash position outweigh the near-term margin and legal/headcount transition headwinds.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$10.00
▲(74.83% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
8.94% Insiders
2.07% Mutual Funds
36.28% Other Institutional Investors
52.58% Public Companies and
Individual Investors